

MagForce

H117: EIB funding to accelerate rollout

New financing from the European Investment Bank (EIB) of up to €35m will support NanoTherm's European rollout for treatment of both brain and prostate cancer patients. In the US, a second clinical treatment site has been established in Texas and the IDE approval process with the FDA continues. In H117, the net loss for the period was €3.0m (H116: €3.2), while gross cash as of 30 June 2017 stood at €7.7m but does not include any drawdowns from the EIB loan, which was signed post period.

EU and US: Implementation of strategy continues

MagForce plans to use the EIB funds to drive NanoTherm roll-out across Europe for treatment of patients with brain tumours; key to the roll-out will be achieving reimbursement in selected European countries. In addition to brain cancer, MagForce now plans to introduce treatment of intermediate risk prostate cancer to Europe. In FY16, MagForce USA updated its pre-clinical NanoTherm trials to meet FDA requirements and will look to continue its discussions in H217 as it aims for Investigational Device Exemption (IDE) approval. MagForce seeks to commercially launch its NanoTherm therapy for prostate cancer into the US in 2018 and in 2016 established a second clinical site in Texas (CHRISTUS Santa Rosa Hospital).

EIB financing enables European expansion

Post period, MagForce agreed a loan of €35m from the EIB, €10m of which was available immediately, with the remaining €25m obtainable in up to four tranches within the next 36 months. The ability to draw down the remaining €25m will be based on certain operational milestones; however, it should be noted that MagForce has no commitment to draw the tranches. Each tranche must be repaid within five years. MagForce's cash position strengthened in HY17 to gross €7.7m (H116: €0.6m). H117 net loss decreased slightly to €3.0m (H116: €3.2m) driven mainly by an increase in revenues to €684k (H116: €143k). However, this was offset predominately by an increase in purchased services.

Valuation: Increasing patient numbers the goal

We expect MagForce to launch its NanoTherm treatment into the broader EU and the US within the next 18 months, which should help to realise value in the near term. Sufficient patient recruitment and the securing of reimbursement is vital to success in both markets (assuming US approval).

Historical financials

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/13	0.0	(6.7)	(0.34)	0.0	N/A	N/A
12/14	0.0	(7.9)	(0.33)	0.0	N/A	N/A
12/15	2.6	(4.5)	(0.18)	0.0	N/A	N/A
12/16	0.5	(7.2)	(0.28)	0.0	N/A	N/A

Source: MagForce accounts. Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Figures above do not include MagForce USA.

Healthcare equipment & services

06 October 2017

Price €7.7
Market cap €203m

Share price graph



Share details

Code	MF6
Listing	Deutsche Börse Scale
Shares in issue	26.3m
Last reported net debt as of 30 June	€0.4m

Business description

MagForce is a German firm with a European approved nanotechnology-based therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour, activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Bull

- US and broader EU sales on near-term horizon.
- Technology is clinically validated.
- CEO track record.

Bear

- Cross-border reimbursement is difficult in the EU.
- Approval in the US is needed before launch.
- Uptake of treatment has been slow to date.

Analysts

Dr Daniel Wilkinson	+44 (0)20 3077 5734
Dr Susie Jana	+44 (0) 20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

H117 results: Funding ready to move strategy forward

MagForce recorded a small reduction in net loss for H117 to €3.0m (H116: €3.2m), mainly as a result of an increase in revenues to €684k (H116: €143k). However, this was largely offset by an increase in purchased services. Other operating income stayed relatively flat at €606k (H116: €602k). Revenue and other income revenues are predominately a result of commercial patient treatment, NanoTherm deliveries to MagForce USA and recharges to subsidiaries. Further breakdown was not provided in the H117 results. The cost of materials and purchased goods increased versus the previous period, while personnel expenses remained largely flat.

Exhibit 1: Financial summary

Year end 31 December	€000s	2013	2014	2015	2016
		HGB	HGB	HGB	HGB
Income statement					
Revenue		0	0	2,576	474
Profit Before Tax (reported)		(1,626)	(1,007)	(1,547)	(7,230)
Net income as reported		(1,628)	(1,008)	(1,547)	(7,231)
EPS (reported) (€)		(0.08)	(0.04)	(0.06)	(0.28)
Dividend per share (c)		0.0	0.0	0.0	0.0
Balance sheet					
Total non-current assets		7,443	15,707	19,533	18,742
Total current assets		10,284	12,999	5,325	1,536
Total assets		17,727	28,707	24,858	20,278
Total liabilities		(2,491)	(4,279)	(1,977)	(4,625)
Net assets		15,236	24,428	22,881	15,653
Shareholders' equity		15,236	24,428	22,881	15,650

Source: MagForce accounts

Net debt as of 30 June 2017 was €0.4m (cash in hand, bank balances and checks reported at €7.7m). In February, Lipps & Associates LLC granted a loan of €400k to MagForce. The loan is due on 30 June 2019 and has a 5% interest rate. In June, a further €3.0m was loaned to MagForce at 4% interest, also due on 30 June 2019. In March, a €5m convertible bond was issued with a maturity of three years, an interest rate of 5% a year and a conversion price of €5/share. In June, MagForce AG raised €5m via a capital raise with M&G International Investments, placing 0.7m shares at €6.94. Post period MagForce agreed a €35m loan from the EIB of which €10m was available for immediate draw down.

Valuation

We expect MagForce to launch its NanoTherm treatment into the broader EU and the US within the next 18 months. In the US, MagForce USA is close to potentially being granted an IDE, which would allow it to start the planned pivotal prostate trial. Assuming approval and the prompt start of the trial, MagForce USA could be approved for treatment of prostate cancer patients by the end of 2018. Prostate cancer represents a major opportunity and will be a key value driver over the mid-term. In the EU, difficulty in attracting cross-border patients has led to slower than anticipated uptake. Glioblastoma (GBM) is an aggressive disease and patients are often unwilling to travel to other countries to receive treatment. MagForce plans to place machines in other European countries, starting in late 2017. A combination of increased awareness and access to treatment could drive revenues in 2018 and beyond. For our detailed valuation methodology, please see our previously [published initiation note](#).

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Any Information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors.

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700

280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor
10017, New York
US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia